Ruffo Frank 4
4 · Aclaris Therapeutics, Inc. · Filed Apr 26, 2021
Insider Transaction Report
Form 4
Ruffo Frank
Chief Financial Officer
Transactions
- Sale
Common Stock
2021-04-22$26.84/sh−30,000$805,218→ 209,059 total - Sale
Common Stock
2021-04-23$27.33/sh−800$21,863→ 179,059 total - Sale
Common Stock
2021-04-26$26.44/sh−100$2,644→ 151,720 total - Sale
Common Stock
2021-04-26$25.79/sh−27,239$702,584→ 151,820 total - Sale
Common Stock
2021-04-23$26.64/sh−29,200$777,797→ 179,859 total
Footnotes (5)
- [F1]These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021.
- [F2]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.51 to $27.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.23 to $27.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $27.23 to $27.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.38 to $26.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.